Mag. (FH) Axel Beer

Despite efforts to amplify tumor-specific T-cell response, no meaningful antitumor activity was yet observed. New technologies show promise of an individual treatment option.

The results of the placebo controlled double blind phase III study Keynote 054 will be presented at the AACR annual meeting.

Combinations of immune checkpoint inhibitors and chemotherapy show promising results. Results of the the KEYNOE 189 study will be presented at the AACR.

Immune checkpoint inhibitors show promise in the treatment of rare mCRC cases with high microsatellite instability.